ENTREMED

Company Fact Sheet

EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMed's drug candidates target disease cells and the blood vessels that nourish them. The Company's goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation and inflammation—processes that are vital to the progression of cancer and other diseases. EntreMed's four clinical-stage product candidates work through both antiproliferative and antiangiogenic mechanisms. The Company's expertise is focused on the development of novel, orally-active drugs against validated targets such as HIF-1α, and new chemical entities associated with Aurora kinase and HDAC inhibition, important targets in the treatment of cancer.

Clinical Trials	Our Business	Our Science
• Multiple Phase 1 and 2 oncology studies with multiple product candidates • Oral formulations provide tremendous benefit over traditional chemotherapeutics • Multiple mechanisms limit drug resistance and target both tumors and their vasculature	• Experienced executive management team focused on execution • Experience in research, clinical management, and commercial and business development • Board pipeline provides multiple opportunities for success • Strong IP position • Prudent resource management	• Extensive expertise in angiogenesis, cell cycle regulation and inflammation • Multiple pathways target key tumor survival mechanisms • Distinguished Scientific Advisory Board • Top notch scientific team with state-of-the-art research facilities in Rockville, MD and Toronto, Ontario

PRODUCT	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
MKC-1	Metastatic Breast Cancer					
	Non-Small Cell Lung Cancer					
	Leukemia					
	Pancreatic Cancer					
	Ovarian/Endometrial Cancers					
ENMD-1198	Advanced Cancer					
Panzem® (2ME2)	Rheumatoid Arthritis					
ENMD-2076	Cancer					

© EntreMed, Inc. March 2008

For additional information please visit our web site at www.entremed.com

EntreMed, Inc.
9640 Medical Center Drive
Rockville, MD 20850

Ginny Dunn, Associate Director, Corporate Communications & Investor Relations
(240) 864-2643 ginnyd@entremed.com

Mark Williamson, Senior Communications Specialist
(240) 864-2645 markw@entremed.com

2008 Clinical and Non-Clinical Milestones

Panzem® NCD + Avastin® combination trial Phase 2 in carcinoid tumors (interim)	1Q08
MKC-1 ovarian/endometrial trial	1Q08
Initiate ENMD-2076 Phase 1 trial in solid tumors	1Q08
MKC-1 combination trial with radiation in pancreatic cancer	2Q08
MKC-1 continuous dosing trial	2Q08
MKC-1 metastatic breast cancer trial	2Q08
MKC-1 + Alimta® Phase 1/2 NSCLC trial—Phase 1 and interim Phase 2	2Q08
Panzem® normal volunteer trial in RA	1H08
Complete ENMD-1198 Phase 1b dose-escalation trial	2Q/3Q08
Initiate ENMD-2076 Phase 1 trial in hematological tumors	3Q08
MKC-1 Phase 1 leukemia trial (interim)	2H08
ENMD-1198 expanded Phase 1 or Phase 2 trial	3Q/4Q08
MKC-1 Phase 2 pancreatic trial (interim)	4Q08
ENMD-1198 Phase 1b dose-escalation trial (interim)	4Q08
ENMD-2076 co-development alliance	2H08/1H09

ENMD-1198 MKC-1 ENMD-2076

Financial Highlights

As of December 31, 2007, the Company had cash and short-term investments of approximately $47.7 million. The Company has cash and short-term investments to support current and planned activities into 2009.

Corporate Executives

EntreMed's management team has aligned the Company's business strategy with its core scientific strengths, while maintaining prudent resource management, fiscal responsibility and accountability. The team has redirected EntreMed's financial resources and R&D strategy to focus on small molecule drug candidates with broad therapeutic potential, manageable development costs, and significant commercial opportunity. Under its senior leadership, EntreMed is moving various small molecule compounds from discovery to clinical trials, including its two lead candidates, Panzem® NCD and MKC-1.

James S. Burns, *President and Chief Executive Officer*
Kenneth W. Bair, *PhD, Senior Vice President, Research & Development*
Cynthia Wong Hu, *Vice President, General Counsel & Secretary*
Dane R. Saglio, *Chief Financial Officer*
Carolyn F. Sidor, *MD, MBA, Vice President & Chief Medical Officer*

Board of Directors

Michael M. Tarnow (Chairman)
James S. Burns
Donald S. Brooks
Dwight L. Bush, Sr.
Ronald Cape, PhD
Jennie Hunter-Cevera, PhD
Peter S. Knight
Mark C. M. Randall

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results may differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings including risks relating to our ability to obtain additional financing; the early-stage products under development; uncertainties relating to clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

ENMD
NASDAQ®
LISTED

© EntreMed, Inc. March 2008